open access

Vol 88, No 10 (2017)
REVIEW PAPERS Gynecology
Published online: 2017-10-31
Get Citation

Novel biomarkers of overactive bladder syndrome

Andrzej Franciszek Wróbel, Tomasz Kluz, Grzegorz Surkont, Edyta Wlaźlak, Paweł Skorupski, Aleksandra Filipczak, Tomasz Rechberger
DOI: 10.5603/GP.a2017.0102
·
Pubmed: 29192418
·
Ginekol Pol 2017;88(10):568-573.

open access

Vol 88, No 10 (2017)
REVIEW PAPERS Gynecology
Published online: 2017-10-31

Abstract

The social aspect of overactive bladder syndrome (OAB) and the lack of objective diagnostic methods for this syndrome have spurred research into its potential biomarkers which can constitute useful diagnostic tools, while also allowing the evaluation of the intensity of clinical symptoms and the efficacy of implemented pharmacotherapy in OAB patients. Due to the complex etiopathogenesis of this syndrome, the researchers are seeking biomarkers connected with inflammation or nerve growth. The aim of this review was to analyse the latest literature data regarding potential biomarkers in OAB. The most promising opportunities are connected with the diagnostic use of the nerve growth factor (NGF), the brain derived neurotrophic factor (BDNF), C-reactive protein (CRP), prostaglandins and cytokines. Despite the most promising results to date having been obtained with regards to neurotrophic factors, it seems that, at the moment, none of these meets the criteria for becoming an isolated OAB marker. It is also suggested that the combined use of several biomarkers will facilitate obtaining the appropriate level of specificity and selectivity to allow their use in clinical practice.

Abstract

The social aspect of overactive bladder syndrome (OAB) and the lack of objective diagnostic methods for this syndrome have spurred research into its potential biomarkers which can constitute useful diagnostic tools, while also allowing the evaluation of the intensity of clinical symptoms and the efficacy of implemented pharmacotherapy in OAB patients. Due to the complex etiopathogenesis of this syndrome, the researchers are seeking biomarkers connected with inflammation or nerve growth. The aim of this review was to analyse the latest literature data regarding potential biomarkers in OAB. The most promising opportunities are connected with the diagnostic use of the nerve growth factor (NGF), the brain derived neurotrophic factor (BDNF), C-reactive protein (CRP), prostaglandins and cytokines. Despite the most promising results to date having been obtained with regards to neurotrophic factors, it seems that, at the moment, none of these meets the criteria for becoming an isolated OAB marker. It is also suggested that the combined use of several biomarkers will facilitate obtaining the appropriate level of specificity and selectivity to allow their use in clinical practice.

Get Citation

Keywords

biomarker, overactive bladder, diagnosis

About this article
Title

Novel biomarkers of overactive bladder syndrome

Journal

Ginekologia Polska

Issue

Vol 88, No 10 (2017)

Pages

568-573

Published online

2017-10-31

DOI

10.5603/GP.a2017.0102

Pubmed

29192418

Bibliographic record

Ginekol Pol 2017;88(10):568-573.

Keywords

biomarker
overactive bladder
diagnosis

Authors

Andrzej Franciszek Wróbel
Tomasz Kluz
Grzegorz Surkont
Edyta Wlaźlak
Paweł Skorupski
Aleksandra Filipczak
Tomasz Rechberger

References (30)
  1. Merighi A, Salio C, Ghirri A, et al. BDNF as a pain modulator. Prog Neurobiol. 2008; 85(3): 297–317.
  2. Obata K, Noguchi K. BDNF in sensory neurons and chronic pain. Neurosci Res. 2006; 55(1): 1–10.
  3. Antunes-Lopes T, Pinto R, Carvalho-Barros S, et al. 883 URINARY LEVELS OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) IN WOMEN WITH OVERACTIVE BLADDER (OAB) SYNDROME CORRELATE WITH THE SEVERITY OF SYMPTOMS. Eur Urol. 2011; 10(2): 277–278.
  4. Pinto R, Lopes T, Silva J, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol. 2010; 58(3): 360–365.
  5. Tyagi P, Barclay D, Zamora R, et al. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol. 2010; 42(3): 629–635.
  6. Chuang YC, Tyagi V, Liu RT, et al. Urine and Serum C-Reactive Protein Levels as Potential Biomarkers of Lower Urinary Tract Symptoms. Urol Sci. 2010; 21(3): 132–136.
  7. Hsiao SM, Lin HH, Kuo HC. The role of serum C-reactive protein in women with lower urinary tract symptoms. Int Urogynecol J. 2012; 23(7): 935–940.
  8. Liao CH, Chung SD, Kuo HC. Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment. Urology. 2011; 78(6): 1373–1378.
  9. Kim JC, Park EY, Seo SIl, et al. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol. 2006; 175(5): 1773–6; discussion 1776.
  10. Yokoyama O, Miwa Y, Oyama N, et al. Antimuscarinic drug inhibits detrusor overactivity induced by topical application of prostaglandin E2 to the urethra with a decrease in urethral pressure. J Urol. 2007; 178(5): 2208–2212.
  11. Liu HT, Tyagi P, Chancellor MB, et al. Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int. 2010; 106(11): 1681–1685.
  12. Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev. 2004; 56(4): 581–631.
  13. Silva-Ramos M, Silva I, Oliveira O, et al. Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome. PLoS One. 2013; 8(5): e64696.
  14. Cheng Y, Mansfield K, Allen W, et al. Correlation between cystometric volumes, ATP release and pH in women with overactive bladder versus controls. Neurourol Urod. 2013; 32(7): 969–973.
  15. Nishijima S, Sugaya K, Kadekawa K, et al. Comparison of the effect of anti-muscarinic agents on bladder activity, urinary ATP level, and autonomic nervous system in rats. Biomed Res. 2009; 30(2): 107–112.
  16. Lamb K, Gebhart GF, Bielefeldt K. Increased nerve growth factor expression triggers bladder overactivity. J Pain. 2004; 5(3): 150–156.
  17. Zvara P, Vizzard MA. Exogenous overexpression of nerve growth factor in the urinary bladder produces bladder overactivity and altered micturition circuitry in the lumbosacral spinal cord. BMC Physiol. 2007; 7: 9.
  18. Kim JC, Park EY, Seo SIl, et al. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol. 2006; 175(5): 1773–6; discussion 1776.
  19. Yokoyama T, Kumon H, Nagai A. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol Urodyn. 2008; 27(5): 417–420.
  20. Liu HT, Chen CY, Kuo HC. Urinary nerve growth factor in women with overactive bladder syndrome. BJU Int. 2011; 107(5): 799–803.
  21. Chen CY, Kuo HC. Novel urinary biomarkers in the diagnosis and assessment of overactive bladder. Incontinence Pelvic Floor Dysfunct. 2009; 3: 20.
  22. Kuo HC, Liu HT, Chancellor MB, et al. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int. 2009; 103(12): 1668–1672.
  23. Hakenberg OW, Linne C, Manseck A, et al. Bladder wall thickness in normal adults and men with mild lower urinary tract symptoms and benign prostatic enlargement. Neurourol Urodyn. 2000; 19(5): 585–593, doi: 10.1002/1520-6777(2000)19:5<585::aid-nau5>3.0.co;2-u.
  24. Robinson D, Anders K, Cardozo L, et al. Can ultrasound replace ambulatory urodynamics when investigating women with irritative urinary symptoms? BJOG. 2002; 109(2): 145–148.
  25. Blatt AH, Titus J, Chan L. Ultrasound measurement of bladder wall thickness in the assessment of voiding dysfunction. J Urol. 2008; 179(6): 2275–8; discussion 2278.
  26. Rechberger T, Nowakowski Ł, Rechberger E, et al. Prevalence of common comorbidities among urogynaecological patients. Ginekol Pol. 2016; 87(5): 342–346.
  27. Panayi DC, Tekkis P, Fernando R, et al. Ultrasound measurement of bladder wall thickness is associated with the overactive bladder syndrome. Neurourol Urodyn. 2010; 29(7): 1295–1298.
  28. Serati M, Salvatore S, Cattoni E, et al. Ultrasound measurement of bladder wall thickness in different forms of detrusor overactivity. Int Urogynecol J. 2010; 21(11): 1405–1411.
  29. Latthe PM, Champaneria R, Khan KS. Systematic review of the accuracy of ultrasound as the method of measuring bladder wall thickness in the diagnosis of detrusor overactivity. Int Urogynecol J. 2010; 21(8): 1019–1024.
  30. Bright E, Oelke M, Tubaro A, et al. Ultrasound estimated bladder weight and measurement of bladder wall thickness--useful noninvasive methods for assessing the lower urinary tract? J Urol. 2010; 184(5): 1847–1854.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl